Tetrabenazine

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Tetrabenazine 是一种 VMAT 抑制剂，用于治疗多动性运动障碍。

Tetrabenazine is a VMAT-inhibitor used for treatment of hyperkinetic movement disorder.(In Vivo):Tetrabenazine (subcutaneous injection, 1-10 mg/kg, once) can reduce the aggressive behavior in a dose-dependent manner and the levels of neurotransmitter molecules NE, DA and 5-HT in adult male mice.Tetrabenazine (intraperitoneal injection, 0-2 mg/kg, once) has selective effects on movement which can significantly attenuate morphine-induced hypermobility but oral tremors and stereotyped behaviors in male ICR mice.Tetrabenazine (intraperitoneal injection, 0.25-2 mg/kg, once a week) increases tremulous jaw movement (TJM) in a dose-dependent manner in adult male Sprague-Dawley rat.

——

Tetrabenazine (subcutaneous injection, 1-10 mg/kg, once) can reduce the aggressive behavior in a dose-dependent manner and the levels of neurotransmitter molecules NE, DA and 5-HT in adult male mice. Tetrabenazine (intraperitoneal injection, 0-2 mg/kg, once) has selective effects on movement which can significantly attenuate morphine-induced hypermobility but oral tremors and stereotyped behaviors in male ICR mice.Tetrabenazine (intraperitoneal injection, 0.25-2 mg/kg, once a week) increases tremulous jaw movement (TJM) in a dose-dependent manner in adult male Sprague-Dawley rat. Animal Model:Adult male MAO A KO or wide type mice aged 1-2 months Dosage:1-10 mg/kg Administration:Subcutaneous injection; once Result:Completely eliminated the aggressive behavior at a concentration of 5 mg/kg and significantly reduced their NE, DA and 5-HT levels.Animal Model:Male ICR mice (10 weeks old)Dosage:0-2 mg/kg Administration:Intraperitoneal injection; once Result:Attenuated the subsequent morphine-induced hypermobility after pretreatment with tetrabenazine. Reduced METH-induced increases in locomotion at 1 mg/kg.Animal Model:Adult male Sprague-Dawley rat weighed 350-450 g Dosage:0.25-2 mg/kg Administration:Intraperitoneal injection; once a weekResult:Induced tremulous jaw movement (TJM) significantly at the concentration of 2 mg/kg and more motor impairments with higher doses such as 3-4 mg/kg.

NSC 169886 | NSC 172187 | Ro 1-9569 | TBZ

GPCR/G Protein

Dopamine Receptor

D2| Synaptic vesicular amine transporter

Neurological Disease

——

58-46-8

317.42

C19H27NO3

>98% (HPLC)

DMSO: 10 mM

O=C1[C@@H](CC(C)C)CN2CCC3=CC(OC)=C(OC)C=C3[C@]2([H])C1

(3S,11bS)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one

(-20℃)

With Ice Pack

≥ 2 years